POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Drug Class Unexpectedly Effective on Breast Cancers

Share this article:
Drug Class Unexpectedly Effective on Breast Cancers
Drug Class Unexpectedly Effective on Breast Cancers

(HealthDay News) -- Drugs that normally target cancer cells defective in DNA homologous recombination repair, poly(ADP-Ribose) polymerase (PARP) inhibitors, are also effective on breast cancer cells positive for human epidermal growth factor receptor 2 (HER2), even in the absence of the repair defect, according to a study published in the Sept. 15 issue of Cancer Research.

Noting that PARP inhibitors are known to be effective on cells defective in homologous recombination repair (e.g., showing promise in clinical trials in BRCA-associated breast and ovarian cancers), Somaira Nowsheen, from the University of Alabama at Birmingham School of Medicine, and colleagues examined the effectiveness of PARP inhibitors on breast cancer cells negative or positive for HER2.

The researchers found that HER2-positive breast cancers were sensitive to PARP inhibitors, even those without a defect in homologous repair. HER2-negative breast cancers could be rendered sensitive to PARP inhibitors in vivo and in vitro by overexpressing HER2, with HER2 reduction abrogating this response. Further experiments showed that the ability of HER2 to inhibit the nuclear factor kappa B signaling pathway was associated with sensitivity to PARP inhibitors.

"Our findings indicate that PARP inhibitors may be a novel therapeutic strategy for sporadic HER2-positive breast cancer patients," Nowsheen and colleagues conclude.

Abstract

Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Breast Cancer

Breast Cancer Markers Commonly Used in Routine Surveillance

Breast Cancer Markers Commonly Used in Routine Surveillance

Medical costs nearly 30 percent higher in these women with early-stage breast cancer.

DOST Imaging May Predict Breast Cancer Response to Chemotherapy

DOST Imaging May Predict Breast Cancer Response to ...

Diffuse Optical imaging (DOST) may be effective for predicting which breast cancer patients will achieve the best response to chemotherapy.

For Patients With HER2-Positive Breast Cancer, Trastuzumab Improves Survival

For Patients With HER2-Positive Breast Cancer, Trastuzumab Improves ...

Addition of trastuzumab (Herceptin) to chemo for breast cancer improves survival.